• RILUTEK ® Tablets 50 mg №56

RILUTEK ® Tablets 50 mg №56

Description for RILUTEK ® Tablets 50 mg №56


Product: tablets, p / o.

Pharmacological properties: a derivative of benzothiazole. Exerts influence on the multilateral mechanism of glutamate neirotransmissii. The proposed mechanism of action riluzola has a complicated structure and includes the following: inhibition of glutamate release; voltazhzavisimyh inactivation of sodium channels, non-competitive receptor blockade of M-O-methyl-aspartic acid stimulation of C-belkovozavisimyh routes of transmission of the pulse.

Riluzol prolongs survival in patients with amyotrophic lateral sclerosis.

Riluzol penetrates through the BBB; in vivo has neuroprotective properties in various experimental models of neural injury by type of cerebral ischemia. In vivo riluzol protects motor neurons from eksaytotoksicheskogo effect of glutamic acid and prevents the death of neurons of the cerebral cortex during hypoxia. In healthy volunteers riluzol at a therapeutic dose have some protective effect during hypoxia due to reduced barometric pressure equivalent to an altitude of 5000 m. Riluzol induces a moderate reduction in the processes of glucose metabolism in the brain that are statistically significant for some areas (parietal, occipital, limbic). Due to the blockade of glutamate neirotransmissii experiment shows muscle relaxant and sedative effects (about 20 recommended daily dose for humans), and also possesses anticonvulsant effect (about 2 recommended doses for humans).

INDICATIONS: amyotrophic lateral sclerosis.

APPLICATION: The recommended daily intake for adults, including elderly people - 100 mg (50 mg every 12 h). With further increase in dose therapeutic effect increases slightly.

CONTRAINDICATIONS: Hypersensitivity to riluzolu.

SIDE EFFECTS: The most frequently reported nausea, vomiting, dizziness, fatigue, rare - abdominal pain, colitis, stomatitis, pancreatitis, peritonitis, anorexia, ulcer bleeding, amnesia, coma, paresthesia, chest pain, back pain, anaphylactoid reaction, eczema, angioedema, hypertension, tachycardia, arrhythmia, anemia, peripheral edema, weight loss, increased activity of ALT, AST, y-glutamyl transferase, CK and bilirubin in serum.

SPECIAL NOTES: in connection with the possibility of drowsiness or dizziness, patients taking riluzol should not drive vehicles or work with other potentially dangerous machinery.

Safety and efficacy riluzola in neurodegenerative processes in children and adolescents have not been studied.

Riluzol should be used with caution in patients with acute liver disease. Recommended that the determination of this serum transferase before treatment and regularly monitor it for the first 3 months of therapy, and in the future - 1 every 3 months during the first year of treatment and periodically thereafter. In patients with elevated ALT levels, the study should be conducted more frequently. If the level of ALT more than 5 times the value of the upper limit of normal, riluzol should be abolished. Reappointment riluzola in such a situation is not recommended.

INTERACTION: riluzol theoretically can affect the pharmacodynamics of drugs that bind to albumin and blood lipoproteins, but the results of the studies showed no competitive interaction riluzola and warfarin, indicating that no unwanted interaction with drugs that bind to plasma proteins (digoxin, imipramine, quinine) . The possibility of negative pharmacokinetic interaction is unlikely.

OVERDOSE: cases are unknown; specific antidote is available. In case of overdose recommended symptomatic and supportive therapy.

RILUTEK ® Tablets 50 mg №56

  • Product Code: 16
  • Availability: In Stock
  • $1,200.00

  • Ex Tax: $1,200.00

Tags: RILUTEK ® Tablets 50 mg №56